ABSTRACT
Background: SARS-CoV-2 has a high mutation rate, resulting in the emergence of multiple variants in a shorter time frame, starting with Wuhan strain during first wave, then Delta during second wave and Omicron during third wave. World faced distressing spread of novel corona virus. The reason for this study was to look at the third flood of SARS-CoV-2, clinical highlights and risk factors in northern India. Method(s): This study involved 1,43,983 individuals for testing the presence of SARS-CoV-2 infection during January 2022 by RT-PCR. The epidemiological record was collected as per the guidelines of ICMR from the patient forms. Result(s): A total of 12.24% individuals were found positive with mean age of 29+/-10 years. Large portion of positive population (63.87%) was asymptomatic. Among the positive population, higher positivity rate was observed in males (57.51%) with age band of 21-40 years (51.17%). Significant association (p value = <0.00001) was found between positivity rate with age, gender and status (symptomatic/ asymptomatic). SARS-CoV-2 was shown to be more prevalent in Patiala, (49.66%) district followed by Ludhiana (24.24%), Sangrur (10.06%), Mansa (7.06%), Shaheed Bhagat Singh Nagar (6.90%) and Malerkotla (2.08%) during second and third week of January 2022. Hypertension and bronchial asthma were the most well-known comorbidities found in the current study. Conclusion(s): In totality, current study showed positivity rate of 12.24% from large population size for SARS CoV-2 from period of 1st January 2022 to 31 January 2022. Current findings include younger age group (21-40 years), high percent of asymptomatic individuals, less disease severity and a little need of hospitalization.Copyright © 2023, Institute of Medico-legal Publication. All rights reserved.
ABSTRACT
Objective: Assess the SARS-CoV2 Spike antibody response in multiple sclerosis (MS) patients on high efficacy immunotherapies. Background: There is limited knowledge about SARS-CoV2 mRNA vaccine response in MS patients on immunotherapy. Design/Methods: Patients with MS, aged 18-65, on fingolimod, siponimod, ofatumumab, or ocrelizumab for at least 3 months prior to first mRNA SARS-CoV2 vaccine (Pfizer or Moderna) were offered enrollment. A cohort of healthy controls who received the mRNA vaccines were also enrolled. Blood samples for the SARS-CoV2 Spike antibody (Anti-SARS-CoV2 S, RocheElecsys) were collected 2-3 months after the second mRNA vaccine. The proportion who seroconverted (antibody>0.4 U/ml), and SARS-CoV2 Spike antibody levels were assessed. Results: A total of 39 MS patients (6 fingolimod, 33 ocrelizumab) and 31 controls were included in this interim analysis. 33%(13/39) of MS patients seroconverted, compared to 100%(31/31) in the control group, with an estimated risk difference of -0.67,(95% confidence interval: -0.81, -0.52;Fisher's exact test, p=9.0∗10-10 ). There was no difference in seroconversion rates between MS patients who received the Pfizer (34%, 10/29) versus the Moderna vaccine (30%, 3/10) (95% confidence interval -0.38, 0.29;Fisher's exact test=1). Seroconversion was found in 100% (31/31) of controls, 66.7% (4/6) of fingolimod-treated patients, and 27.3% (9/33) of ocrelizumab-treated patients (three group comparison, Fisher's exact test p-value =2.7∗10 -10). The median Spike antibody level was <0.4 U/ml in MS patients, and 1,663 U/ml in controls (Wilcoxon rank sum test, p-value= 1.0∗10-12 ). The median Spike antibody level in the ocrelizumab group was <0.4 U/ml, 3.45 U/ml in the fingolimod group, and 1,663 U/ml in the control group (Kruskal Wallis test, p-value=5.9∗10-12 ). Total IgG correlated with Spike antibody levels in the ocrelizumab-treated group only (Spearman correlation, p=0.025). Conclusions: MS patients on ocrelizumab and fingolimod have significantly lower rates of seroconversion, and lower median Spike antibody levels in response to the mRNA SARS-CoV2 vaccines compared to controls.
ABSTRACT
Background: The most common teaching method in medical institutes in India and throughout the globe is standard lesson-based teaching. E-learning is the use of internet technology to facilitate conscious learning and increase knowledge and competences, notably during the COVID-19 epidemic. Aim and Objectives: The aim of study was to develop a module for an interactive disease-based e-learning teaching session to impart knowledge to undergraduate medical students regarding the microbiological diagnostic techniques for enteric fever/the given organism with objectives of the study was (i) to investigate how Phase II MBBS students feel about e-learning;(ii) to evaluate the impact of this intervention on students;and (iii) to encourage application of this imparted knowledge and skill for rapid, precise, and early diagnosis of the disease. Material and Methods: The research was conducted at the department of microbiology. This was done for the session 2020–2021 of Phase II undergraduate students. All the second professional MBBS were enrolled in the study n = 229 and were better informed about the definition of e-learning. The course material was provided in the form of PowerPoint presentations, questionnaires, and text questions using Google Docs. Students provided feedback in the form of a semi-structured pre-validated set of questions at the conclusion of the week, and the collected data were quantitatively analyzed. There were both closed-ended and open-ended questions in the survey. Results: The results of the feedback questionnaire revealed that the program was of benefit to the students. Nearly 77% of students felt the new teaching and learning method enhanced their grasp of the courses and that the issues presented were important to them. Conclusion: The students responded in a positive way to the new teaching and learning method. It was informative, applicable, and effective to the students. It also increased the level of communication and feedback between teacher and students. To conclude, in the medical program, e-resources may be used to enhance conventional lesson-based instruction.
ABSTRACT
Background:Healthcare workers (HCWs) have high risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to the increased likelihood of clinical exposure during patient management. The study objective was to determine the seroprevalence of antibodies to SARS-CoV-2 and its predictors among hospital employees. Methods:The cross-sectional study was conducted in a teaching hospital from August 2020 to September 2020, among 1401 employees, including 1217 healthcare workers in New Delhi, India. The serum samples were examined for IgG an- tibodies to SARS-CoV-2 using the COVID KavachTM-Anti-SARS-CoV-2 IgG Antibody Detection ELISA kit. Data were col- lected electronically using the EpiCollect mobile platform. P < 0.05 was considered statistically significant. Results:A total of 169 (12.1%) participants had detectable IgG antibodies to SARS-CoV-2. The highest seropositivity rate was observed in the administrative staff (20.1%), while it was lowest among medical doctors (5.5%) (p<0.001). Conclusions:The probability of HCW-to-HCW, or patient-to-HCW transmission of SARS-CoV-2 was found to be lower than the risk of acquisition of infection from general population